Replies to post #247839 on Biotech Values

[semi_infinite]

Someone posted a summary for a group of companies including nktx.

Tough 2023 ytd for smid-cap CAR-T/NK (-27% med/-15% mean)🔴vs. XBI (0.1%) 🟢
Tough day/yr for allogeneic ("off-the-shelf") CAR-T/NK👎
• $NKTX -42% (-53% ytd) despite reporting "encouraging" activity
• $ACET -52% (-76% ytd) despite reporting "Positive Data"
• $FATE +2% (-50%… pic.twitter.com/wOdsfuxCjR

— BiopharmIQ by Amp (@BiopharmIQ) June 27, 2023

[semi_infinite]

Door slammed on Tessa CAR-T. Shut down announced due to lack of financing or buyout interest. They had AUTO program in clinic and working on ALLO.

https://endpts.com/singapore-cancer-cell-therapy-startup-tessa-therapeutics-to-shut-down/